Milnocor (Milrinone)

Milrinone, the active ingredient in Milnocor, is a phosphodiesterase 3 inhibitor presented as an injectable solution for intravenous use. It is employed to improve cardiac performance in patients with severe heart failure or cardiogenic shock. GNH USA supplies Milnocor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as a positive inotropic and vasodilator in acute cardiac conditions. - Acute decompensated heart failure: increases cardiac output and reduces systemic vascular resistance. - Cardiogenic shock: supports hemodynamics by enhancing myocardial contractility. - Bridge to definitive therapy (e.g., transplant or mechanical support): provides temporary circulatory support while awaiting definitive treatment.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often transient. - Nausea: occasional gastrointestinal upset. - Arrhythmias: premature beats or tachycardia. - Hypotension: drop in blood pressure, especially with rapid infusion.

Serious or Rare Side Effects: - Severe ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: marked decrease in platelet count.

Milnocor requires careful clinical monitoring and adherence to safety guidelines. - Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. - Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk. - Renal function: adjust dosing in patients with impaired clearance. - Concomitant vasodilators: avoid excessive hypotension when combined with other vasodilators. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Milrinone can interact with several drug classes, influencing its safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Other potent inotropes (e.g., dopamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response, requiring dose adjustments. - Diuretics: can exacerbate electrolyte disturbances, increasing arrhythmia risk. - Nitrates or other vasodilators: may potentiate hypotensive effects.